<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Enlivex Therapeutics Ltd — News on 6ix</title>
<link>https://6ix.com/company/enlivex-therapeutics-ltd</link>
<description>Latest news and press releases for Enlivex Therapeutics Ltd on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 23 Apr 2026 12:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/enlivex-therapeutics-ltd" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835637878dffbe2df0ef438.webp</url>
<title>Enlivex Therapeutics Ltd</title>
<link>https://6ix.com/company/enlivex-therapeutics-ltd</link>
</image>
<item>
<title>Enlivex to Present Phase IIa 3-month and 6-month Data of Allocetra at OARSI 2026 World Congress</title>
<link>https://6ix.com/company/enlivex-therapeutics-ltd/news/enlivex-to-present-phase-iia-3-month-and-6-month-data-of-allocetra-at-oarsi-2026-world-congress</link>
<guid isPermaLink="true">https://6ix.com/company/enlivex-therapeutics-ltd/news/enlivex-to-present-phase-iia-3-month-and-6-month-data-of-allocetra-at-oarsi-2026-world-congress</guid>
<pubDate>Thu, 23 Apr 2026 12:30:00 GMT</pubDate>
<description>Nes-Ziona, Israel, April 23, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “Enlivex” or the “Company”), a quality longevity company powered by a prediction markets treasury, today announced that it will present two poster abstracts at the Osteoarthritis Research Society International (OARSI) 2026 World Congress on Osteoarthritis, taking place April 23-26, 2026, in West Palm Beach, Florida, USA. The presentations will feature 3-month and 6-month endpoints clinical data from the Phase IIa (</description>
</item>
<item>
<title>Enlivex Announces Second Regulatory Approval for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis</title>
<link>https://6ix.com/company/enlivex-therapeutics-ltd/news/enlivex-announces-second-regulatory-approval-for-phase-2b-trial-of-allocetra-in-age-related-primary-moderate-to-severe-knee-osteoarthritis-1</link>
<guid isPermaLink="true">https://6ix.com/company/enlivex-therapeutics-ltd/news/enlivex-announces-second-regulatory-approval-for-phase-2b-trial-of-allocetra-in-age-related-primary-moderate-to-severe-knee-osteoarthritis-1</guid>
<pubDate>Tue, 21 Apr 2026 04:00:00 GMT</pubDate>
<description>· Approval by the Danish Medicines Agency (DKMA) for enrolling patients in Denmark follows the recently announced FDA clearance to initiate the Phase 2b study</description>
</item>
<item>
<title>Ondo Global Markets Tokenizes Enlivex’s Ordinary Shares</title>
<link>https://6ix.com/company/enlivex-therapeutics-ltd/news/ondo-global-markets-tokenizes-enlivexs-ordinary-shares</link>
<guid isPermaLink="true">https://6ix.com/company/enlivex-therapeutics-ltd/news/ondo-global-markets-tokenizes-enlivexs-ordinary-shares</guid>
<pubDate>Wed, 08 Apr 2026 12:30:00 GMT</pubDate>
<description>Nes-Ziona, Israel, April 08, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “Enlivex” or the “Company”), a quality longevity company powered by a prediction markets treasury, today announced that Ondo Finance (“Ondo”) has launched ENLVon, the Ondo tokenized representation of ENLV’s ordinary shares on Ondo’s Global Markets platform. Through the launch of ENLVon, non-U.S. retail and institutional investors can gain direct economic exposure to Enlivex’s ordinary shares through digital infrast</description>
</item>
<item>
<title>Enlivex Announces $21 Million Debt Financing, Decentralized Prediction Markets RAIN Token-Related Updates and $20 Million Share Repurchase Program</title>
<link>https://6ix.com/company/enlivex-therapeutics-ltd/news/enlivex-announces-dollar21-million-debt-financing-decentralized-prediction-markets-rain-token-related-updates-and-dollar20-million-share-repurchase-program</link>
<guid isPermaLink="true">https://6ix.com/company/enlivex-therapeutics-ltd/news/enlivex-announces-dollar21-million-debt-financing-decentralized-prediction-markets-rain-token-related-updates-and-dollar20-million-share-repurchase-program</guid>
<pubDate>Tue, 24 Mar 2026 04:00:00 GMT</pubDate>
<description>$21 Million debt financing, convertible to ENLV ordinary shares at fixed $2.69175 per share, a 264% premium to the Nasdaq closing price on March 20, 2026,</description>
</item>
<item>
<title>Quality Longevity Company Enlivex Receives Investigational New Drug (IND) Clearance from the FDA for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis</title>
<link>https://6ix.com/company/enlivex-therapeutics-ltd/news/quality-longevity-company-enlivex-receives-investigational-new-drug-ind-clearance-from-the-fda-for-phase-2b-trial-of-allocetra-in-age-related-primary-moderate-to-severe-knee-osteoarthritis</link>
<guid isPermaLink="true">https://6ix.com/company/enlivex-therapeutics-ltd/news/quality-longevity-company-enlivex-receives-investigational-new-drug-ind-clearance-from-the-fda-for-phase-2b-trial-of-allocetra-in-age-related-primary-moderate-to-severe-knee-osteoarthritis</guid>
<pubDate>Mon, 23 Mar 2026 04:00:00 GMT</pubDate>
<description>Enlivex’s first regulatory approval for a late-stage global Phase 2b study in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis following the</description>
</item>
<item>
<title>Enlivex Therapeutics Shares to Trade Exclusively on Nasdaq</title>
<link>https://6ix.com/company/enlivex-therapeutics-ltd/news/enlivex-therapeutics-shares-trade-exclusively-130000897</link>
<guid isPermaLink="true">https://6ix.com/company/enlivex-therapeutics-ltd/news/enlivex-therapeutics-shares-trade-exclusively-130000897</guid>
<pubDate>Fri, 23 Jan 2026 13:00:00 GMT</pubDate>
<description>Voluntarily Delisting of Ordinary Shares from Trading on the Tel Aviv Stock Exchange to Promote U.S.-Based Trading, Reduce Administrative Costs of Dual Listing Nes-Ziona, Israel, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq and TASE: ENLV) (“Enlivex” or “the Company”), a clinical-stage macrophage reprogramming immunotherapy biotech company and operator of the world’s first prediction markets-focused digital asset treasury centered on RAIN, today announced that it has initi</description>
</item>
<item>
<title>Enlivex Announces Closing of Previously Announced $212,000,000 Private Placement</title>
<link>https://6ix.com/company/enlivex-therapeutics-ltd/news/enlivex-announces-closing-of-previously-announced-dollar212000000-private-placement</link>
<guid isPermaLink="true">https://6ix.com/company/enlivex-therapeutics-ltd/news/enlivex-announces-closing-of-previously-announced-dollar212000000-private-placement</guid>
<pubDate>Wed, 26 Nov 2025 05:00:00 GMT</pubDate>
<description>– Enlivex has adopted the world’s first RAIN prediction markets token digital asset treasury strategy, via RAIN token accumulation. – RAIN is a fully</description>
</item>
<item>
<title>Enlivex Announces Positive 6-Month Topline Data –Demonstrating Durable and Persistent Pain Reduction and Improved Function in Primary Age-Related Patients with Moderate to Severe Knee Osteoarthritis</title>
<link>https://6ix.com/company/enlivex-therapeutics-ltd/news/enlivex-announces-positive-6-month-114000442</link>
<guid isPermaLink="true">https://6ix.com/company/enlivex-therapeutics-ltd/news/enlivex-announces-positive-6-month-114000442</guid>
<pubDate>Mon, 24 Nov 2025 11:40:00 GMT</pubDate>
<description>Nes-Ziona, Israel, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. ( Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced positive six-month efficacy data from the Phase IIa stage of its randomized, multi-country Phase I/II Allocetra™ trial (ENX-CL-05-001) in patients with moderate to severe knee osteoarthritis (OA). The six-month follow-up has now been completed for all patients. The results re-affirm the three-month data rep</description>
</item>
<item>
<title>Enlivex Announces $212,000,000 Private Placement to Initiate World’s First Prediction Markets Digital Asset Treasury Strategy, via RAIN token Accumulation, and the Appointment of Matteo Renzi, Former Prime Minister of Italy, to its Board</title>
<link>https://6ix.com/company/enlivex-therapeutics-ltd/news/enlivex-announces-dollar212000000-private-placement-to-initiate-worlds-first-prediction-markets-digital-asset-treasury-strategy-via-rain-token-accumulation-and-the-appointment-of-matteo-renzi-former-prime-minister-of-italy-to-its-board</link>
<guid isPermaLink="true">https://6ix.com/company/enlivex-therapeutics-ltd/news/enlivex-announces-dollar212000000-private-placement-to-initiate-worlds-first-prediction-markets-digital-asset-treasury-strategy-via-rain-token-accumulation-and-the-appointment-of-matteo-renzi-former-prime-minister-of-italy-to-its-board</guid>
<pubDate>Mon, 24 Nov 2025 05:00:00 GMT</pubDate>
<description>- Upon the closing of the private placement, Enlivex will adopt the world’s first RAIN prediction markets token digital asset treasury strategy, via RAIN</description>
</item>
<item>
<title>Enlivex Therapeutics to Present Phase IIa 3-month Data of Allocetra in Patients with Moderate-to-Severe Knee Osteoarthritis at the ACR Convergence 2025</title>
<link>https://6ix.com/company/enlivex-therapeutics-ltd/news/enlivex-therapeutics-present-phase-iia-121500496</link>
<guid isPermaLink="true">https://6ix.com/company/enlivex-therapeutics-ltd/news/enlivex-therapeutics-present-phase-iia-121500496</guid>
<pubDate>Tue, 28 Oct 2025 12:15:00 GMT</pubDate>
<description>Ness-Ziona, Israel, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that it will present a late-breaking poster abstract at the American College of Rheumatology (ACR) Convergence 2025, taking place October 24–29 at McCormick Place Convention Center in Chicago, Illinois. The presentation will feature clinical data from the recently announced Phase IIa (ENX-CL-05-001) 3-month</description>
</item>
<item>
<title>D. Boral Capital to Host KOL Webinar With World Leading Experts Featuring Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program</title>
<link>https://6ix.com/company/enlivex-therapeutics-ltd/news/d-boral-capital-host-kol-121500748</link>
<guid isPermaLink="true">https://6ix.com/company/enlivex-therapeutics-ltd/news/d-boral-capital-host-kol-121500748</guid>
<pubDate>Mon, 29 Sep 2025 12:15:00 GMT</pubDate>
<description>Nes-Ziona, Israel, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, will participate in a live investor webinar, “Advancing Inflammatory Disease Treatment: Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program,” hosted by D. Boral Capital on September 30, 2025, at 10:00 AM Eastern Time. The discussion will bring together leading key opinion leaders (KOLs) in musculoskeletal d</description>
</item>
<item>
<title>Enlivex CEO Issues Letter to Shareholders Outlining Strategic Roadmap Following Positive Phase IIa Allocetra™ Results</title>
<link>https://6ix.com/company/enlivex-therapeutics-ltd/news/enlivex-ceo-issues-letter-shareholders-120000328</link>
<guid isPermaLink="true">https://6ix.com/company/enlivex-therapeutics-ltd/news/enlivex-ceo-issues-letter-shareholders-120000328</guid>
<pubDate>Thu, 11 Sep 2025 12:00:00 GMT</pubDate>
<description>Allocetra™ demonstrated statistically significant and clinically meaningful improvements in pain and function in Phase IIa trial in primary osteoarthritis patients Six-month data expected November 2025; Phase IIb trial initiation planned for Q2 2026 Nes-Ziona, Israel, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Enlivex”), a clinical-stage macrophage reprogramming immunotherapy company, today issued the following update to shareholders from Chief Executive Off</description>
</item>
<item>
<title>Enlivex Announces Issuance of New Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis</title>
<link>https://6ix.com/company/enlivex-therapeutics-ltd/news/enlivex-announces-issuance-patent-application-120000739</link>
<guid isPermaLink="true">https://6ix.com/company/enlivex-therapeutics-ltd/news/enlivex-announces-issuance-patent-application-120000739</guid>
<pubDate>Tue, 09 Sep 2025 12:00:00 GMT</pubDate>
<description>Nes-Ziona, Israel, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the issuance of an Israeli patent, numbered 290470, titled, “THERAPEUTIC APOPTOTIC CELLS FOR TREATMENT OF OSTEOARTHRITIS”. The patent will provide Enlivex with added intellectual property protection in Israel through at least 2040 with claims covering methods of using Allocetra™ to treat subjects with osteo</description>
</item>
<item>
<title>Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis</title>
<link>https://6ix.com/company/enlivex-therapeutics-ltd/news/enlivex-announces-positive-topline-data-114500691</link>
<guid isPermaLink="true">https://6ix.com/company/enlivex-therapeutics-ltd/news/enlivex-announces-positive-topline-data-114500691</guid>
<pubDate>Mon, 18 Aug 2025 11:45:00 GMT</pubDate>
<description>ENX-CL-05-001 Trial: 3-months topline data - In the overall modified intention-to-treat (mITT) population, improvements across all efficacy and secondary endpoints, including 24% reduction in knee pain and 26% improvement in knee function, were observed in the AllocetraTM treatment arm vs placebo; moreover, 72% reduction in knee pain and 95% improvement in knee function were observed for age-related primary osteoarthritis patients compared with placebo – a substantial, clinically meaningful and</description>
</item>
<item>
<title>Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Osteoarthritis Trial on August 18 Webinar</title>
<link>https://6ix.com/company/enlivex-therapeutics-ltd/news/enlivex-present-3-month-topline-123000494</link>
<guid isPermaLink="true">https://6ix.com/company/enlivex-therapeutics-ltd/news/enlivex-present-3-month-topline-123000494</guid>
<pubDate>Thu, 14 Aug 2025 12:30:00 GMT</pubDate>
<description>Webinar to Review Results from Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Allocetra™ in Patients with Moderate to Severe Knee Osteoarthritis Nes-Ziona, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced it will host a webinar on Monday, August 18, 2025, at 8:00 AM Eastern Time to present and discuss 3-month topline results from the Phas</description>
</item>
<item>
<title>Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data</title>
<link>https://6ix.com/company/enlivex-therapeutics-ltd/news/enlivex-reaffirms-august-18-2025-123000719</link>
<guid isPermaLink="true">https://6ix.com/company/enlivex-therapeutics-ltd/news/enlivex-reaffirms-august-18-2025-123000719</guid>
<pubDate>Mon, 28 Jul 2025 12:30:00 GMT</pubDate>
<description>Nes-Ziona, Israel, July 28, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that all 134 patients in its Phase II stage of its randomized, controlled, blinded Phase I/II trial of Allocetra™ in patients with moderate to severe knee osteoarthritis, have completed a follow-up period of at least three months, the trial’s primary timepoint for measurement of key endpoints. The data are b</description>
</item>
<item>
<title>Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology</title>
<link>https://6ix.com/company/enlivex-therapeutics-ltd/news/enlivex-therapeutics-present-clinical-data-123000798</link>
<guid isPermaLink="true">https://6ix.com/company/enlivex-therapeutics-ltd/news/enlivex-therapeutics-present-clinical-data-123000798</guid>
<pubDate>Tue, 10 Jun 2025 12:30:00 GMT</pubDate>
<description>Ness-Ziona, Israel, June 10, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that it will present a poster at the European Alliance of Associations for Rheumatology (EULAR) European Congress of Rheumatology, taking place June 11-14, 2025, in Barcelona, Spain. The Company’s presentation will feature data from the ongoing clinical study evaluating Allocetra™, Enlivex’s proprietary, of</description>
</item>
<item>
<title>Enlivex Selected to Present at Israeli BioMed 2025 Conference</title>
<link>https://6ix.com/company/enlivex-therapeutics-ltd/news/enlivex-selected-present-israeli-biomed-120000767</link>
<guid isPermaLink="true">https://6ix.com/company/enlivex-therapeutics-ltd/news/enlivex-selected-present-israeli-biomed-120000767</guid>
<pubDate>Tue, 20 May 2025 12:00:00 GMT</pubDate>
<description>Presentation to highlight Allocetra™ and the therapeutic potential of macrophage reprogramming in inflammatory diseases Ness-Ziona, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Company has been selected to present at the upcoming Israeli BioMed 2025 Conference, taking place May 21–23, 2025 in Tel Aviv, Israel. The Company’s presentation is titled “Enlivex</description>
</item>
<item>
<title>Enlivex Therapeutics to Showcase Allocetra’s Potential in Osteoarthritis at OARSI 2025 World Congress</title>
<link>https://6ix.com/company/enlivex-therapeutics-ltd/news/enlivex-therapeutics-showcase-allocetra-potential-123000648</link>
<guid isPermaLink="true">https://6ix.com/company/enlivex-therapeutics-ltd/news/enlivex-therapeutics-showcase-allocetra-potential-123000648</guid>
<pubDate>Wed, 23 Apr 2025 12:30:00 GMT</pubDate>
<description>Presentations to underscore AllocetraTM’s novel mechanism targeting immune imbalance in joint disease Ness-Ziona, Israel, April 23, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that it will present two poster abstracts at the Osteoarthritis Research Society International (OARSI) 2025 World Congress on Osteoarthritis, taking place April 24-27, 2025, in Incheon (Seoul), South Korea</description>
</item>
<item>
<title>Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis</title>
<link>https://6ix.com/company/enlivex-therapeutics-ltd/news/enlivex-announces-completion-enrollment-phase-123000491</link>
<guid isPermaLink="true">https://6ix.com/company/enlivex-therapeutics-ltd/news/enlivex-announces-completion-enrollment-phase-123000491</guid>
<pubDate>Mon, 21 Apr 2025 12:30:00 GMT</pubDate>
<description>Nes-Ziona, Israel, April 21, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Company completed enrollment of all patients in the Phase II stage of its randomized, controlled, blinded Phase I/II trial of Allocetra™ in patients with moderate to severe knee osteoarthritis. Overall, 133 patients were randomized and treated in the Phase II stage. Oren Hershkovitz, Ph.D, CEO of E</description>
</item>
</channel>
</rss>